Sign in

CIK 0001658551

  • Non-accelerated filer
  • Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464600503
Phone
+1 617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
  1. 4 Option exercise Chief Commercial Officer acquired 25,000 shares (option exercise)
  2. 4 Open-market buy Director bought 4,000 shares at $14.97 ($59,880)
  3. 4 Grant or award Chief Medical Officer acquired 58,333 shares (grant or award)
  4. 3 Insider Initial Statement of Ownership
  5. 4 Option exercise Co-Chief Executive Officer acquired 63,694 shares (option exercise)
  6. 4 Gift Chief Financial Officer gave 11,072 shares (gift)
  7. 4 Option exercise Chief Financial Officer acquired 18,165 shares (option exercise)
  8. 4 Gift 10% owner gave 2,000,000 shares (gift)
  9. 4 Planned sale Chief Legal Officer sold 6,164 shares at $20.88 ($128,686)
  10. 4 Option exercise Chief Commercial Officer acquired 20,000 shares (option exercise)
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Gift Chief Commercial Officer gave 1,580 shares (gift)
  16. 4 Gift Chief Legal Officer gave 500 shares (gift)
  17. 4 Planned sale Chief Financial Officer sold 32,500 shares at an average $26.94 ($875,451)
  18. 4 Planned sale Chief Medical Officer sold 11,965 shares at $29.03 ($347,358)
  19. 4/A Conversion Chief Financial Officer acquired 19,482 shares (conversion)
  20. 3/A Insider 3/A

Page 7 of 11 · 207 filings